NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neuron loss and α-synuclein aggregation. Increasing evidence indicates that blood-brain barrier (BBB) dysfunction in the neurovascular unit (NVU) is an early pathological event driving PD progression, rather than a secondary consequence. AMP-activated protein kinase (AMPK), a key cellular metabolic sensor, is activated by oxidative stress and endoplasmic reticulum stress induced by α-synuclein aggregates, and participates in regulating endothelial barrier function. This review systematically summarizes the pathological evidence of early BBB injury in PD, elaborates on the dual role of AMPK in BBB regulation, and highlights the value of phosphoproteomics in deciphering AMPK's downstream signaling networks. We propose the "α-synuclein-AMPK-phosphorylation network-BBB dysfunction" axis, discuss pharmacological clues from traditional Chinese medicine, and outline future research directions. This review provides a novel integrated perspective for understanding PD neurovascular pathology and lays a theoretical foundation for identifying early intervention targets by targeting AMPK-regulated NVU protection.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.